Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Feb 19, 2014
NEWARK, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen 34th Annual Health Care Conference in Boston. Revance management is scheduled to present on Wednesday, March 5, 2014 at 9:20 am ET. Interested parties can access the live audio ...
Feb 11, 2014
NEWARK, Calif., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its initial public offering of 6,900,000 shares of common stock at a public offering price of $16.00 per share. T...
Feb 5, 2014
NEWARK, Calif., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Revance), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per...
Apr 2, 2013
CONTACT: Lauren Silvernail Chief Financial Officer and EVP Corporate Development 510-742-3415 lsilvernail@revance.com NEWARK, California — April 2, 2013 — Revance Therapeutics, Inc. (Revance), a privately held specialty biopharmaceutical company developing novel botulinum toxin products for use in aestheti...
Mar 25, 2013
CONTACT: Revance Therapeutics, Inc. Niquette L. Hunt Senior Vice President, Commercial Development NEWARK, California—March 25, 2013 — Revance Therapeutics, Inc. (Revance) today announced the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President of Corporate Development effect...
Oct 8, 2012
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif.—October 8, 2012 — Revance Therapeutics, Inc. (Revance) today announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation (NYSE:MRX) concerni...
Jun 10, 2011
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – June 10, 2011 – Revance Therapeutics, Inc. (“Revance”) today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital (Nov...
Oct 22, 2010
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – October 22, 2010 – Revance Therapeutics, Inc. (“Revance”) today announced that the results of two Phase 2b clinical trials on RT001, a topical botulinim toxin type A which is under investig...
Jan 4, 2010
CONTACT: Revance Therapeutics, Inc. Niquette Hunt, SVP, Commercial Development (510) 742-3400 NEWARK, Calif. – January 4, 2010 – Revance Therapeutics, Inc. (“Revance”) today announced the first $25M closing of a $35 million Series D financing. The round was led by Essex Woodlands Health Ventures Fun...
Jul 28, 2009
CONTACT: Medicis Pharmaceutical Corporation Kara Stancell Executive Director, Investor Relations & Corporate Communications (480) 291-5854 Revance Therapeutics, Inc. Niquette Hunt Senior Vice President, Commercial Development (510) 742-3464 SCOTTSDALE, Ariz. and NEWARK, Calif. – July 2...
Page: FirstPrevious ...
11
NextLast
= add release to Briefcase
Shareholder Tools